Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.
On many occasions, one had to absorb a significant degree of shock and act as a facilitator, mediator or referee. A rousing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback